LHRH agonist treatment of breast cancer and gynecological malignancies: A review

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 67, Issue 1, 1996, Pages 27-33

  Burger, Curt W ^a   Prinssen, Helma M ^a   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gynecological malignancies; LHRH agonist; Treatment of breast cancer

Indexed keywords

GONADORELIN AGONIST;

BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG USE; GYNECOLOGIC CANCER; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0030000176     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-2115(96)02424-4     Document Type: Review

References (74)

1. Miller WR. Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Mol Biol 1990; 37: 467-480.
2. Klijn JGM, de Jong FH. Treatment with luteinizing-hormone releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1982; i: 1213-1216.
3. Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA. LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 1985; 23: 867-873.
4. Bianco AR, Rosso R, Calabresi F, Fiorentino M, Lopez M, Sismondi PG, Lenti R, Fosser V, De Placido S, Perrone F, Pronzato P, Carlini P, Fornasiero A, Veltri E, Zola P, Farinacci M, Gulisano M, Artioli R. LH-RH analogue zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer. Eur J Gynaecol Oncol 1991; 12: 429-437.
5. Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI. The use of an LH-RH agonist (ICI 118630, zoladex) in advanced premenopausal breast cancer. Br J Cancer 1986; 53: 629-636.
6. Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Jaenicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H, Strunz P, Schachner-Wuenschmann E, Bastert G, Maass H. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 1989; 7: 1113-1119.
7. Schmid H, Schachner-Wuenschmann E, Kaufmann M. Zoladex als Depot GnRH-Agonist beim praemenopausalen metastasierten Mammakarzinom. Arch Gynecol Obstet 1989; 245: 741-743.
8. Bajetta E, Zilembo N, Buzzoni R, Celio L, Zampino MG, Colleoni M, Oriana S, Attili A, Sacchini V, Martinetti A. Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. Oncology 1994; 51: 262-269.
9. Manni A, Santen R, Harvey H, Lipton A, Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev 1986; 7: 89-94.
10. Filicori M, Flamigni C. GnRH agonists and antagonists. Curr Clin Status 1987; 34: 63-82.
11. Saphner T, Troxel AB, Tormey DC, Neuberg D, Robert NJ, Pandya KJ, Edmonson JH, Rosenbluth RJ, Abeloff MD. Phase II study of goserelin for patients with postmenopausal metastatic breast cancer. J Clin Oncol 1993; 11: 1529-1535.
12. Plowman PN, Nicholson RI, Walker KJ. Remission of postmenopausal breast cancer during treatment with the luteinizing hormone releasing hormone agonist ICI 118630. Br J Cancer 1986; 54: 903-909.
13. Cassano A, Astone A, Garufi C, Noviello MR, Pietrantonio F, Barone C. A response in advanced post-menopausal breast cancer during treatment with the luteinizing hormone releasing hormone agonist - zoladex. Cancer Lett 1989; 48: 123-124.
14. Martikainen H, Penttinen J, Huhtaniemi L, Kaupilla A. Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy. Gynecol Oncol 1989; 35: 406-408.
15. Kaupilla A, Bangah M, Burger H, Martikainen H. GnRH agonist analog therapy in advanced/recurrent granulosa cell tumors: further evidence of a role of inhibin in monitoring response to treatment. Gynecol Endocrinol 1992; 6: 271-274.
16. Kullander S, Rausing A, Schally AV. LHRH agonist treatment in ovarian cancer. Klijn JGM, editor. Hormonal manipulation of cancer: peptides, growth factors, and new (anti)steroidal agents. New York: Raven Press, 1987; 353-356.
17. Parmar H, Phillips RH, Rustin G, Lightman SL, Schally AV. Therapy of advanced ovarian cancer with D-Trp-6-LHRH (decapeptyl) microcapsules. Biomed Pharmacother 1988; 42: 531-538.
18. Jäger W, Wildt L, Lang N. Beobachtungen des Verlaufs fortgeschrittener Ovarialkarzinome nach medikamentöser Reduktion hypophysärer Gonadotropine. Geburtshilfe Frauenheilkd 1989; 49: 611-617.
19. Sevelda P, Vavra N, Fitz R, Barrada M, Salzer H, Baur M, Dittrich C. Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer. Int J Gynecol Cancer 1992; 2: 160-162.
20. Gallagher CJ, Oliver RT, Oram DH, Fowler CG, Blake PR, Mantell BS, Slevin ML, Hope-Stone HF. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 1991; 98: 1037-1041.
21. Kitasato H, Fabiani B, Busuttil M, Reynes M, Hillova J, Hill M, Mathe G. Regression of the malignant aspect of intraepithelial neoplasias following an LH-RH agonist treatment and detection of human papillomavirus by molecular hybridization. Biomed Pharmacother 1989; 43: 183-185.
22. Zur Hausen H. Papillomaviruses in human cancer. Cancer 1987; 59: 1692-1696.
23. Loong EP, Wong FW. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone releasing hormone for presumed uterine fibroid. Fertil Steril 1990; 54: 530-531.
24. Meyer WR, Mayer AR, Diamond MP, Carcangiu ML, Schwartz PE, DeCherney AH. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990; 75: 529-531.
25. Brower ST, Schally AV, Redding TW, Hollander VP. Differential effects of LHRH and somatostatin analogs on human breast cancer. J Surg Res 1992; 52: 6-14.
26. Meyer JS, Rao BR, Stevens SC, White WL. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 1977; 40: 2290-2298.
27. Tinnemans JGM, Beex LVA, Wobbes T, Sluis RF, Raemakers JMM, Benraad T. Steroid-hormone receptors in nonpalpable and more advanced stages of breast cancer. A contribution to the biology and natural history of carcinoma of the female breast. Cancer 1990; 66: 1165-1167.
28. Adami HO, Killander D. Prediction of survival in breast cancer: principles and current status of hormone receptors and DNA content as prognostic factors. Acta Chir Scand Suppl 1984; 519: 25-34.
29. Raemaekers JMM, Beex LVAM, Koenders AJM, Pieters GFFM, Smals AGH, Benraad TJ, Kloppenborg PWC. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 1985; 6: 123-131.
30. Blamey RW, Bishop HM, Blake JRS, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K. Relationship between primary breast tumour receptor status and patient survival. Cancer 1980; 46: 2765-2769.
31. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-2888.
32. Blanco G, Alavaikko M, Ojala A, Collan Y, Heikkinen M, Hietanen T, Aine R, Taskinen PJ. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients. Anticancer Res 1984; 4: 383-390.
33. Slotman BJ, Rao BR. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res 1980; 8: 417.
34. Kuehnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem 1987; 26: 393-397.
35. Iversen OE, Skaarland E, Utaaker E. Steroid receptor content in human ovarian tumors: survival of patients with ovarian carcinoma related to steroid receptor content. Gynecol Oncol 1986; 23: 65-76.
36. Slotman BJ, Kuehnel R, Rao BR, Dijkhuizen GH, de Graaff J, Stolk JG. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 1989; 33: 76-81.
37. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993; 71: 1467-1470.
38. Nicholson RI, Walker KJ, Turkes A, Turkes AO, Dyas J, Blamey RW, Cambell FC, Robinson MRG, Griffiths K. Therapeutic significance and the mechanism of action of the LHRH agonist ICI 118630 in breast and prostate cancer. J Steroid Biochem 1984; 20: 129-135.
39. Harvey HA, Lipton A, Max D. LHRH agonist treatment of breast cancer: a phase II study in the USA. Klijn JGM, Paridaens R, Foekens JA, editors. Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. New York: Raven Press, 1987; 18: 321-329.
40. Judd HL, Lucas WE, Yen SSC. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974; 118: 793-797.
41. Crighton IL, Dowsett M, Lal A, Smith IE. Use of luteinizing hormone-releasing hormone agonist (leuprolin) in advanced post-menopausal breast cancer: clinical and endocrine effects. Br J Cancer 1989; 60: 644-648.
42. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of oestradiol in postmenopausal women. Obstet Gynecol 1982; 59: 680-686.
43. Santen RJ, Boucher AE, Santner SJ, Henderson IC, Harvey HA, Lipton A. Inhibition of aromatase as a treatment of breast carcinoma in postmenopausal women. J Lab Clin Med 1987; 109: 278.
44. Enriori CL, Reforzo-Membrives J. Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review. Gynecol Oncol 1984; 17: 1-21.
45. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstendione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130: 448-455.
46. Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD, Ballon SC. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1980; 136: 859-871.
47. Davidson BJ, Gambone JC, Lagasse LD, Castaldo TW, Hammond GL, Siiteri PK, Judd HL. Free estradiol in postmenopausal women with or without endometrial cancer. J Clin Endocrinol Metab 1981; 52: 404-408.
48. Heber D, Swerdloff RS. Down-regulation of pituitary gonadotropin secretion in postmenopausal females by continuous gonadotropin-releasing hormone administration. J Clin Endocrin Metab 1981; 52: 171-172.
49. Harris AL, Carmichael J, Cantwell BMJ, Dowsett M. Zoladex: endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer 1989; 59: 97-99.
50. Dowsett M, Cantwell B, Lal A, Jeffcoate SL, Harris AL. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab 1988; 66: 672-676.
51. Harvey HA, Lipton A, Santen RJ, Hershey MS, Escher GC, Hardy MA, Glode LM, Segaloff A, Landau RL, Schneir H, Max DT. Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Am Soc Clin Oncol 1981; 22: 444 (Abstract C-436).
52. Mathé G, Kelling R, Prévot G, Vovan ML, Gastiaburu J, Prévot G, Vannetzel JM, Despax R, Jasmin C, Lèvi F, Musset M, Machover D, Ribaud, Misset JL. Phase II trial of D-Trp-6-LH-RH in advanced breast cancer. Eur J Cancer Clin Oncol 1986; 22: 723 (Abstract III-L).
53. Bradlow HL. A reassessment of the role of breast tumor aromatization. Cancer Res Suppl 1982; 42: 3382.
54. Thijssen JHH, Blankenstein MA, Miller WR, Milewicz A. Estrogens in tissues: uptake from peripherial circulation or local production. Steroids 1987; 50: 297-306.
55. Edery M, Goussard J, Dehennin L, Scholler R, Reiffsteck J, Drosdowsky MA. Endogenous oestradiol 17B concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur J Cancer 1981; 17: 115-120.
56. O'Neill JS, Miller WR. Aromatase activity in breast adipose tissue from women with benign and malignant diseases. Br J Cancer 1987; 56: 601-604.
57. Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hershey D, Bartholomew MJ, Antle CE. Aromatase activity in primary and metastatic human breast cancer. Cancer 1987; 59: 779-782.
58. Pasqualini JR, Schatz B, Varin C, Nguyen BL. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J Steroid Biochem Molec Biol 1992; 41: 323-329.
59. Stein RC, Dowsett M, Medley A, Gazet JC, Ford HT, Coombes RC. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990; 62: 679-683.
60. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem 1992; 43: 155-159.
61. Harvey HA, Lipton A, Max DT, Pearlman HG, Diaz-Perches R, de la Garza J. Effective medical castration produced by GnRH analog leuprolide in metastatic breast cancer. Proc Am Soc Clin Oncol 1984; 3: 111 (Abstract C-435).
62. Lissoni P, Barni S, Crispino S, Cattaneo G, Tancini G. Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer. Tumori 1988; 74: 303-308.
63. + , hormonal untreated advanced breast cancer patients. Second International Symposium on "Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents", Program and Abstracts, Rotterdam, The Netherlands, 52 (Abstract 118).
64. Dixon AR, Robertson JF, Jackson L, Nicholson RI, Walker KJ, Blamey RW. Goserelin (zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br J Cancer 1990; 62: 868-870.
65. Brambilla C, Escobedo A, Artioli R, Lechuga MJ, Motta M. Treatment of pre-menopausal advanced breast cancer with goscrelin - a long-acting luteinizing hormone releasing hormone agonist. Anti Cancer Drugs 1991; 3: 3-8.
66. Blamey RW, Jonat W, Kaufmann M, Bianco AR, Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 1992; 28A: 810-814.
67. Neskovic-Konstantinovic ZB, Vuletic LB, Nikolic-Stanojevic LI, Susnjar SV, Jelic SB, Brankovic-Magic MV, Radulovic SS. Therapeutic and endocrine effects of decapeptyl, synthetic LH-RH agonistic analogue in premenopausal women with metastatic breast cancer. Oncology 1994; 51: 95-101.
68. Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 1985; 54: 903-909.
69. Schwartz L, Guiochet N, Keiling R. Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer. Cancer 1988; 62: 2498-2500.
70. Parmar H, Nicoll J, Stockdale A, Cassoni A, Phillips RH, Lightman SL, Schally AV. Advanced ovarian carcinoma: response to the agonist D-Trp-6-LHRH. Cancer Treat Rep 1985; 69: 1341.
71. Kavanagh JJ, Roberts W, Townsend P, Hewitt S. Leuprolide acetate in the treatment of refractory or persistent ovarian cancer. J Clin Oncol 1989; 7: 115-118.
72. Phillips RH, Parmar H, Lightman SL. D-Trp-6-LHRH: an important non-toxic treatment for advanced ovarian cancer [Abstract]. ESGO 6: Sixth international congress of gynaecological oncology. Versailles, France, 1989.
73. Namer M, Willemse PHB, Guastalla PJ, Nooy M, Kerbrat B, van de Burg MEL, Renard J, Vermorken JB. D-Trp-6-LHRH (decapeptyl) in patients with advanced ovarian carcinoma: a phase II study of the EORTC gynecological cancer cooperative group (GCCG). Proc Eur Conf Clin Oncol 1990; 5: (Abstr P-1111).
74. Lind MJ, Millward MJ, Cantwell BMJ, Carmichael J, Harris AL. A phase II trial of goserelin ("zoladex") in relapsed epithelial ovarian cancer. Br J Cancer 1990; 62: 518.